Drug news
FDA approves Anturol (Watson Pharma) for Overactive Bladder treatment
FDA has approved Anturol (oxybutynin) from Antares Pharma/Watson Pharma as a topical gel 3% for the treatment of Overactive Bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency. The active ingredient is delivered transdermally, and not metabolized by the liver in the same way as orally administered oxybutynin. This results in a low level of side effects, such as dry mouth and constipation. Under an exclusive licensing agreement, Watson anticipates launching the product in 2012.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins